Clinics
Splenomegaly; chronic phase (lasts about 3 years) with maintained cell's normal activities, followed by accelerated phase(s) (blasts still 30%; blood data: WBC:100 X 10 9 /l and more during chronic phase, with basophilia; a few blasts; thrombocytosis may be present; low leucocyte alkaline phosphatases; typical acute leukaemia (AL) blood data at the time of myeloid or lymphoid-type blast crisis.
Cytology
Hyperplastic bone marrow; granulocytes proliferation, with maturation; followed by typical AL cytology (see: t(9;22)(q34;q11) in ALL, t(9;22)(q34;q11) in ANLL).
Treatment
alphaIFN therapy or allogeneic bone marrow transplantation (BMT), donor leukocytes infusions.
Prognosis
Median survival: 4 years with conventional therapy (hydroxyurea, busulfan), 6 years with aIFN therapy; allogeneic bone marrow transplantation may cure the patient; otherwise, the best treatment to date associates interferon a, hydroxyurea and cytarabine.
Cytogenetics

Cytogenetics morphological
All CML have a t(9;22), at least at the molecular level (see below); but not all t(9;22) are found in CML: this translocation may also be seen in ALL, and in ANLL (see: t(9;22)(q34;q11) in ALL, t(9;22)(q34;q11) in ANLL), and the same genes are involved in the three diseases; in CML, the chromosomal anomaly persists during remission, in contrast with AL cases.
Cytogenetics molecular
Is a useful tool for diagnostic ascertainment in the case of a 'masked Philadelphia' chromosome, where chromosomes 9 and 22 all appear to be normal, but where cryptic insertion of 3' ABL within a chromosome 22 can be demonstrated.
Additional anomalies
1-May be present at diagnosis (in 10%, possibly with unfavourable significance), or may appear during course of the disease, they do not indicate the imminence of a blast crisis, although these additional anomalies also emerge frequently at the time of acute transformation; 2-These are: +der(22), +8, i(17q), +19, most often, but also: +21, -Y, -7, -17, +17; acute transformation can also be accompanied with t(3;21)(q26;q22) (1% of cases); near haploidy can occur; of note, although rare, is the occurrence of chromosome anomalies which are typical of a given BC phenotype (e.g. t(15;17) in a promyelocytic transformation, dic(9;12) in a CD10+ lymphoblastic BC...); +8, +19, +21, and i(17q) occur more often in myeloid -rather than lymphoid-blast crises and apparent t(V;22) or t(9;V), where V is a variable.
Variants
Chromosome, are found in 5-10% of cases; however, 9q34-3'ABL always joins 22q11-5'BCR in true CML; the third chromosome and breakpoint is, at times, not random. In a way, masked Philadelphia chromosomes (see above) are also variants. 
Genes involved and proteins
ABL
Result of the chromosomal anomaly
Hybrid gene
Description 1-The crucial event lies on der(22), id est 5' BCR/3' ABL hybrid gene is pathogenic, while ABL/BCR may or may not be expressed; 2-Breakpoint in ABL is variable over a region of 200 kb, often between the two alternative exons 1b and 1a, sometimes 5' of 1b, or 3' of 1a, but always 5' of exon 2; 3-Breakpoint in BCR is in a narrow region, therefore called M-bcr (for major breakpoint cluster region), a cluster of 5.8 kb, between exons 12 and 16, also called b1 to b5 of M-bcr; most breakpoints being either between b2 and b3, or between b3 and b4. Transcript 8.5 kb mRNA, resulting in a 210 kDa chimeric protein. Detection RT-PCR for minimal residual disease detection.
Fusion protein
Description P210 with the first 902 or 927 amino acids from BCR; BCR/ABL has a cytoplasmic localization, in contrast with ABL, mostly nuclear. It is now clearly established that BCR-ABL is the oncogene responsible for the occurrence of CML. The hybrid protein has an increased protein kinase activity compared to ABL: 3BP1 (binding protein) binds normal ABL on SH3 domain, which prevents SH1 activation; with BCR/ABL, the first (N-terminal) exon of BCR binds to SH2, hidding SH3 which, as a consequence, cannot be bound to 3BP1; thereof, SH1 is activated. Oncogenesis A-Major molecular pathways activated by BCR-ABL. 1-BCR/ABL activates RAS signaling through the GRB2 adaptor molecule which interacts specifically with the Y177 of BCR. 2-PI3-K (phosphatidyl inositol 3' kinase) pathway is also activated with secondary activation of the AKT/PKB pathway. 4-Molecular events associated with blast crisis: P53 mutation, methylation of ABL promoter, telomere shortening, Abl-1 inactivation.
To be noted
Note 1-Blast crisis is sometimes at the first onset of CML, and those cases may be undistinguishable from true ALL or ANLL with t(9;22) and P210 BCR/ABL hybrid; 2-JCML (juvenile chronic myelogenous leukaemia) is not the juvenile form of chronic myelogenous leukaemia: there is no t(9;22) nor BCR/ABL hybrid in JCML, and clinical features (including a worse prognosis) are not similar to those found in CML; 3-so called BCR/ABL negative CML should not be called so! 4-P53 is altered in 1/3 of BC-CML cases. 5-Most recent developments: Evidence of telomere shortening in CML cells during progression into blast crisis.
